Nasus Pharma Ltd. NSRX 深 沪
等待开盘 03-27 09:30:00 美东时间
2.40
-0.360
-13.04%
华盛通- 最 高2.6666
- 今 开2.53
- 成交量 4.59万股
- 最 低 2.345
- 昨 收 2.76
- 总市值 2810.59万
- 52周最高 9.9899
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.285
- 委 比 0.00%
- 总股本 1171.08万
- 历史最高 9.9899
- 量 比 0.36
- 振 幅 11.65%
- 历史最低 2.285
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
今天 10:22
Nasus Pharma Ltd. reports FY results
Nasus Pharma Ltd. press release (NSRX): FY Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, Nasus had cash, cash equivalents and marketable securities of $4.3 million, compar...
03-25 21:17
Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To EpiPen; Pivotal Trial Planned For !4
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the filing of its annual report on
03-25 21:03
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Nasus Pharma reported positive Phase 2 results for NS002, an intranasal epinephrine powder for anaphylaxis, showing faster absorption than EpiPen®. They plan a pivotal study for Q4 2026, with a potential NDA submission. The company is also advancing NS003 (ondansetron for chemotherapy-induced nausea) and NS004 (metabolic disorders) toward first-in-human studies in H2 2026. With strong cash reserves, Nasus is well-funded to support its pipeline ex...
03-25 13:00
美股夜盘 | 正业生物涨35.07%，Blue Gold涨31.43%
正业生物涨35.07%；Blue Gold涨31.43%；QVC Group, Inc. Class A涨23.60%
03-23 15:02
What's Going On With Nasus Pharma Stock On Wednesday
Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are falling and what the data shows.
03-18 23:11
Nasus Pharma Stock Hits 52-Week Low - Here's Why
Nasus Pharma (NSRX) hits a 52-week low despite positive Phase 2 data for its EpiPen rival. See why the stock is down 43% today.
03-17 01:01
Nasus Pharma shares are trading lower after the company reported results from its Phase 2 clinical study of NS002. The reported data is lower than January's interim data.
Nasus Pharma shares are trading lower after the company reported results from i...
03-16 23:31
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Zevra Therapeutics (NASDAQ:ZVRA) stock moved upwards by 20.6% to $11.0...
03-10 05:05
Nasus Pharma To Present Topline Analysis From Its Phase 2 Repeated Dose Clinical Study Of NS002
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's
03-09 20:34
